SLC5A2 and Hyperkalemia: Combination therapy may be also attractive not only for enhanced efficacy but also for reasons of safety, since the risk of hyperkalemia associated with the use of MRAs appears to be mitigated by the potassium-lowering action of SGLT-2 inhibitors [44].